News

Intellia Therapeutics Receives Orphan Drug Designation for NTLA-2002 in the EU

1 Mins read

Intellia Therapeutics, a leading biotechnology company, has recently been granted orphan drug designation by the European Commission for their investigational therapy, NTLA-2002. This therapy shows promise in the treatment of hereditary angioedema (HAE), a condition characterized by potentially life-threatening swelling attacks.

Positive Impact on Stock

Following this significant development, Intellia Therapeutics experienced a surge in their shares, with a 10% increase, reaching $26.10. This comes as a relief to the company, as their stock had hit a low point of $22.67 earlier this week, resulting in a 51% overall decrease in the past year.

Promising Research on NTLA-2002

NTLA-2002 is an innovative in vivo CRISPR-based therapy specially designed to prevent swelling attacks in individuals with HAE. This therapy has shown potential in combating this condition and offering hope to patients.

Orphan Drug Designation Process

In receiving orphan drug designation from the European Union, Intellia Therapeutics has successfully met the rigorous criteria set by the European Medicines Agency Committee for Orphan Medicinal Products. This designation is reserved for therapies intended to treat, prevent, or diagnose life-threatening or chronically debilitating diseases that affect a limited number of people in the EU population (not exceeding five in 10,000 individuals).

Recognition and Future Potential

Intellia Therapeutics’ NTLA-2002 has not only been granted orphan drug designation by the European Commission but has also received this prestigious recognition from the U.S. Food and Drug Administration. With five special regulatory designations already obtained for NTLA-2002, there is growing confidence in the therapeutic potential of this innovative solution.

Related posts
News

Risk mitigation

4 Mins read
Asian economies should cooperate to jointly lower their overreliance on dollar-denominated assets The economic and trade policies implemented by the current administration…
News

Cloud mining revolutionizes the way to increase the value of crypto assets: Ripplecoin Mining allows XRP, BTC, and Solana holders to achieve daily income | Business Upturn

3 Mins read
Weston, Massachusetts, July 16, 2025 (GLOBE NEWSWIRE) — As the cryptocurrency market continues to fluctuate, more and more investors are looking for…
News

Republicans declared it 'crypto' week in the House. It's not going as planned

1 Mins read
WASHINGTON (AP) — A trio of cryptocurrency bills that had been expected to pass the House this week stalled on Tuesday after…

Leave a Reply

Your email address will not be published. Required fields are marked *